Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20017809 | 0.81 | ALDH1A1 (0.41) | TSHRCYP2C19PDCD1CD274ALDH1A1 | |
| SCHEMBL585949 | 0.80 | NR1H4 (0.58) | NR1H4TSHRCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23785507 | 0.79 | ALDH1A1 (0.39) | TSHRPDCD1CD274ALDH1A1 | |
| SCHEMBL30216932 | 0.77 | ALDH1A1 (0.43) | TSHRALDH1A1SRC | |
| SCHEMBL13177068 | 0.77 | ALDH1A1 (0.43) | TSHRALDH1A1SRC | |
| SCHEMBL19089142 | 0.76 | HPGD (0.39) | NR1H4TSHRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7529284 | 0.76 | NR1H4 (0.54) | NR1H4TSHRCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL25189609 | 0.76 | KMT2A (0.51) | NR1H4TSHRCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2704056 | 0.74 | ALDH1A1 (0.45) | TSHRCYP1A2LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL10732696 | 0.74 | NPC1 (0.49) | NR1H4TSHRCYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853218-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| EP-2041093-B1 | PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-7700599-B2 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GLAXO GROUP LIMITED (GB) | 2010-04-20 | — | — | US | disclosed |
| US-20090192160-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2009-07-30 | — | — | US | disclosed |
| EP-2041093-A1 | PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| US-20080027065-A1 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GLAXO GROUP LIMITED (GB) | 2008-01-31 | — | — | US | disclosed |
| WO-2008000729-A1 | PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027065-A1 | G protein coupled receptor inhibitors (Gpr38) such as 6-[(4-fluorophenyl)oxy]-N-methyl-N-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)-3-pyridinecarboxamide for treatment of gastric stasis in an enterally fed patient | GPR68, GPR88, GPR3 | NR1H4 84/4885TSHR 691/4885CYP1A2 2669/4885 |
| US-20090192160-A1 | COMPOUNDS | GPR68, GPR88, GPBAR1 | NR1H4 21/4885TSHR 1183/4885CYP1A2 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.